Paratek Pharmaceuticals, a leading biopharmaceutical company, is set to unveil groundbreaking research at IDWeek 2023. The company focuses on the development and commercialization of innovative therapies for life-threatening diseases and public health threats. Paratek has announced that new data from its scientific and investigator-initiated research programs on NUZYRA (omadacycline) will be presented at the upcoming IDWeek conference.
IDWeek 2023, a hybrid conference, will be held from October 11th to 15th at the Boston Convention and Exhibition Center. The conference schedule can be accessed online. It is important to note that all IDWeek abstracts are embargoed until October 11th at 8:00 a.m. ET.
Paratek Pharmaceuticals invites conference attendees to visit their onsite Booth #1024 from October 11th to 15th. They are also encouraging participation in various events throughout the conference.
Paratek Pharmaceuticals, Inc., known for its focus on developing and commercializing life-saving therapies for civilian, government, and military use, currently has NUZYRA (omadacycline) as its lead commercial product. NUZYRA is an oral and intravenous antibiotic used for the treatment of community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI) in adults. The company has collaborated with Zai Lab for the development and commercialization of omadacycline in the greater China region while retaining all remaining global rights.
Additionally, Paratek is conducting a Phase 2b study with NUZYRA to explore its potential for treating non-tuberculous mycobacterial (NTM) pulmonary disease caused by Mycobacterium abscessus complex. With an estimated addressable market of $1 billion in the United States, this rare disease represents a significant opportunity for Paratek Pharmaceuticals.
Paratek Pharmaceuticals has exclusively licensed the US rights and rights to the greater China territory for SEYSARA (sarecycline), an oral therapy for the treatment of moderate to severe acne vulgaris, to Almirall, LLC. They retain the development and commercialization rights for sarecycline in the rest of the world.
In 2019, Paratek received a contract from the US Department of Health and Human Services’ Biomedical Advanced Research and Development Authority (BARDA), which is now valued at up to $304 million. The contract supports the development of omadacycline for pulmonary anthrax and the US-based commercial manufacturing of NUZYRA.
NUZYRA, a modernized tetracycline, is a novel antibiotic available in both oral and intravenous formulations. It is designed to overcome tetracycline resistance and is effective against a wide spectrum of bacteria, including drug-resistant strains, Gram-positive and Gram-negative bacteria, and atypical pathogens.
Paratek Pharmaceuticals’ groundbreaking research at IDWeek 2023 is eagerly anticipated, and attendees are encouraged to engage with the company at their booth and participate in the scheduled events. The company’s commitment to developing innovative therapies for life-threatening diseases and public health threats continues to drive their research and development efforts.
For more information about Paratek Pharmaceuticals, visit their official website or follow them on LinkedIn and Twitter.
